Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
K ReichJonathan Ian SilverbergKim A PappMette DeleuranN KatohBruce StroberLisa A BeckM de Bruin-WellerT WerfelF ZhangP BiswasM D DiBonaventuraG ChanS A FarooquiU KerkmannC ClibbornPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
In patients with moderate-to-severe AD, long-term abrocitinib treatment resulted in clinically meaningful improvement in patient-reported symptoms of AD, including QoL.